Are 20 human papillomavirus types causing cervical cancer?

Journal of Pathology

Volumn 234, Issue 4, 2014, Pages 431-435

  Arbyn, Marc ^a   Tommasino, Massimo ^b   Depuydt, Christophe ^c   Dillner, Joakim ^d  

^a UNIVERSITY OF ANTWERP   (Belgium)

^b INTERNATIONAL AGENCY FOR RESEARCH ON CANCER   (France)

^c Sonic Healthcare   (Belgium)

^d KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Biomarkers; Carcinogenesis; Cervical cancer; Human papillomavirus

Indexed keywords

CYCLIN D1; MESSENGER RNA; PROTEIN P16; PROTEIN P53; RETINOBLASTOMA PROTEIN;

HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN PAPILLOMAVIRUS TYPE 26; HUMAN PAPILLOMAVIRUS TYPE 31; HUMAN PAPILLOMAVIRUS TYPE 33; HUMAN PAPILLOMAVIRUS TYPE 35; HUMAN PAPILLOMAVIRUS TYPE 39; HUMAN PAPILLOMAVIRUS TYPE 45; HUMAN PAPILLOMAVIRUS TYPE 51; HUMAN PAPILLOMAVIRUS TYPE 52; HUMAN PAPILLOMAVIRUS TYPE 53; HUMAN PAPILLOMAVIRUS TYPE 56; HUMAN PAPILLOMAVIRUS TYPE 58; HUMAN PAPILLOMAVIRUS TYPE 59; HUMAN PAPILLOMAVIRUS TYPE 66; HUMAN PAPILLOMAVIRUS TYPE 67; HUMAN PAPILLOMAVIRUS TYPE 68; HUMAN PAPILLOMAVIRUS TYPE 70; HUMAN PAPILLOMAVIRUS TYPE 73; MALIGNANT TRANSFORMATION; META ANALYSIS (TOPIC); NONHUMAN; NOTE; PAPILLOMAVIRUS INFECTION; PHYLOGENY; PROTEIN EXPRESSION; SYSTEMATIC REVIEW (TOPIC); UTERINE CERVIX CANCER; VIRUS CARCINOGENESIS; WART VIRUS; FEMALE; PAPILLOMA VIRUS; UTERINE CERVIX TUMOR; VIROLOGY;

FEMALE; HUMANS; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; UTERINE CERVICAL NEOPLASMS;

EID: 84910630584     PISSN: 00223417     EISSN: 10969896     Source Type: Journal    
DOI: 10.1002/path.4424     Document Type: Note

References (21)

1. IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. Biological agents: a review of human carcinogens. IARC Monogr Eval Carcinog Risks Hum 2012; 100B: 1-475.
2. Tommasino M. The human papillomavirus family and its role in carcinogenesis. Semin Cancer Biol 2014; 26: 13-21.
3. Hiller T, Poppelreuther S, Stubenrauch F, Iftner T. Comparative analysis of 19 genital human papillomavirus types with regard to p53 degradation, immortalization, phylogeny, and epidemiologic risk classification. Cancer Epidemiol Biomarkers Prev 2006; 15: 1262-1267.
4. Mansour M, Touka M, Hasan U, et al. E7 properties of mucosal human papillomavirus types 26, 53 and 66 correlate with their intermediate risk for cervical cancer development. Virology 2007; 367: 1-9.
5. de Sanjose S, Quint WG, Alemany L, et al. Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. Lancet Oncol 2010; 11: 1048-1056.
6. Kleter B, van Doorn LJ, Schrauwen L, et al. Development and clinical evaluation of a highly sensitive PCR-reverse hybridization line probe assay for detection and identification of anogenital human papillomavirus. J Clin Microbiol 1999; 37: 2508-2517.
7. Halec G, Alemany L, Lloveras B, et al. Pathogenic role of the eight probably/possibly carcinogenic HPV types 26, 53, 66, 67, 68, 70, 73 and 82 in cervical cancer. J Pathol 2014; 4: 441-451.
8. Halec G, Schmitt M, Dondog B, et al. Biological activity of probable/possible high-risk human papillomavirus types in cervical cancer. Int J Cancer 2013; 132: 63-71.
9. Arbyn M, Castellsagué X, de Sanjosé S, et al. Worldwide burden of cervical cancer in 2008. Ann Oncol 2011; 22: 2675-2686.
10. Bzhalava D, Guan P, Franceschi S, Dillner J, Clifford G. Asystematic review of the prevalence of mucosal and cutaneous human papillomavirus types. Virology 2013; 445: 224-231.
11. Arbyn M, Benoy IH, Simoens C, et al. Pre-vaccination distribution of HPV types in women attending at cervical cancer screening in Belgium. Cancer Epidemiol Biomarkers Prev 2009; 20: 321-330.
12. Schmitt M, Depuydt C, Benoy I, et al. Prevalence and viral load of 51 genital human papillomavirus types and 3 subtypes. Int J Cancer 2013; 132: 2395-2403.
13. Depuydt CE, Criel AM, Benoy IH, et al. Changes in type-specific human papillomavirus load predict progression to cervical cancer. J Cell Mol Med 2012; 16: 3096-3104.
14. Schiffman MA, Khan MJ, Solomon D, et al. A study of the impact of adding HPV types to cervical cancer screening and triage tests. J Natl Cancer Inst 2005; 97: 147-150.
15. Schmitt M, Depuydt C, Benoy I, et al. Multiple HPV infections with high viral loads are associated with cervical lesions but do not differentiate grades of cervical abnormalities. J Clin Microbiol 2013; 51: 1458-1464.
16. Bosch FX, Burchell AN, Schiffman M, et al. Epidemiology and natural history of human papillomavirus infections and type-specific implications in cervical neoplasia. Vaccine 2008; 26 (suppl 10): K1-16.
17. Smelov V, Elfstrom KM, Johansson AL, et al. Long-term HPV type-specific risks for high-grade cervical intraepithelial lesions: a 14-year follow-up of a randomized primary HPV screening trial. Int J Cancer 2014; DOI:10.1002/ijc.29085.
18. Tjalma WA, Depuydt CE. Cervical atypical glandular cells and false negative HPV testing: a dramatic reality of the wrong test at the right place. Eur J Gynaecol Oncol 2014; 35: 117-120.
19. Walboomers JM, Jacobs MV, Manos M, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999; 189: 12-19.
20. Arbyn M, Ronco G, Anttila A, et al. Evidence regarding HPV testing in secondary prevention of cervical cancer. Vaccine 2012; 30(suppl 5): F88-99.
21. Eklund C, Forslund O, Wallin KL, Dillner J. Global improvement in genotyping of human papillomavirus DNA: the 2011 HPV Lab-Net International Proficiency Study. J Clin Microbiol 2014; 52: 449-459.